J. Ma, A. Weisberg, J.P. Griffin, D.E. Vaughan, A.B. Fogo, N.J. Brown 

Slides:



Advertisements
Similar presentations
Volume 72, Issue 7, Pages (October 2007)
Advertisements

Volume 78, Issue 12, Pages (December 2010)
Volume 65, Issue 1, Pages (January 2004)
Inflammatory cytokines in acute renal failure
Volume 82, Issue 6, Pages (September 2012)
Volume 78, Issue 4, Pages (August 2010)
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Volume 54, Issue 3, Pages (September 1998)
Volume 78, Issue 12, Pages (December 2010)
Volume 72, Issue 4, Pages (August 2007)
Volume 68, Issue 3, Pages (September 2005)
Volume 72, Issue 1, Pages (July 2007)
Volume 65, Issue 1, Pages (January 2004)
Volume 68, Issue 5, Pages (November 2005)
Volume 81, Issue 3, Pages (February 2012)
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats  Julie Chao, Jenny J. Zhang, Kuei-Fu Lin,
Volume 58, Issue 6, Pages (December 2000)
Volume 66, Issue 6, Pages (December 2004)
Volume 75, Issue 9, Pages (May 2009)
Volume 70, Issue 7, Pages (October 2006)
Volume 69, Issue 1, Pages (January 2006)
Volume 68, Issue 1, Pages (July 2005)
Volume 59, Issue 5, Pages (May 2001)
Apoptosis in the kidneys of patients with type II diabetic nephropathy
Volume 69, Issue 1, Pages (January 2006)
VEGF receptor 2 blockade leads to renal cyst formation in mice
Volume 54, Issue 5, Pages (November 1998)
Volume 63, Issue 5, Pages (May 2003)
Volume 76, Issue 3, Pages (August 2009)
Volume 81, Issue 3, Pages (February 2012)
Targets to retard the progression of diabetic nephropathy
Volume 70, Issue 3, Pages (August 2006)
Volume 53, Issue 5, Pages (May 1998)
Volume 81, Issue 3, Pages (February 2012)
Role of CD8+ cells in the progression of murine adriamycin nephropathy
Volume 70, Issue 2, Pages (July 2006)
Glomerular injury is exacerbated in diabetic integrin α1-null mice
Prevention of mesangial sclerosis by bone marrow transplantation
Blockade of NFκB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney  Yee-Yung Ng, Chun-Cheng Hou, Wansheng.
Volume 64, Issue 1, Pages (July 2003)
Neil J. Paloian, Elizabeth M. Leaf, Cecilia M. Giachelli 
Volume 72, Issue 3, Pages (August 2007)
Volume 71, Issue 7, Pages (April 2007)
Volume 66, Issue 4, Pages (October 2004)
Volume 57, Issue 1, Pages (January 2000)
Volume 74, Issue 6, Pages (September 2008)
B. Li, T. Morioka, M. Uchiyama, T. Oite  Kidney International 
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 72, Issue 7, Pages (October 2007)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 78, Issue 1, Pages (July 2010)
Volume 80, Issue 5, Pages (September 2011)
Volume 85, Issue 1, Pages (January 2014)
Volume 69, Issue 11, Pages (June 2006)
Fibrosis and renal aging
Volume 73, Issue 3, Pages (February 2008)
Volume 58, Issue 3, Pages (September 2000)
TGF-β type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis  C.Y. Song, B.C. Kim, H.K. Hong,
H. Raffi, J.M. Bates, Z. Laszik, S. Kumar  Kidney International 
Volume 62, Issue 3, Pages (September 2002)
Volume 58, Issue 4, Pages (October 2000)
Volume 69, Issue 3, Pages (February 2006)
Volume 76, Issue 8, Pages (October 2009)
A nest in renal fibrosis?
Volume 74, Issue 9, Pages (November 2008)
Volume 73, Issue 5, Pages (March 2008)
Effect of prenatal dexamethasone on rat renal development
Volume 65, Issue 1, Pages (January 2004)
Alex B. Magil, Kathryn Tinckam  Kidney International 
Presentation transcript:

Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury  J. Ma, A. Weisberg, J.P. Griffin, D.E. Vaughan, A.B. Fogo, N.J. Brown  Kidney International  Volume 69, Issue 6, Pages 1064-1072 (March 2006) DOI: 10.1038/sj.ki.5000201 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 Effect of vehicle and aldosterone infusion on systolic blood pressure (SBP) in wild-type (WT) and plasminogen activator inhibitor-1 (PAI-1(−/−)) mice.*P=0.025 versus vehicle-infused wild-type, †P=0.007 versus aldosterone-infused PAI-1(−/−). Kidney International 2006 69, 1064-1072DOI: (10.1038/sj.ki.5000201) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 Renal histological changes in wild-type and PAI-1(−/−) mice given aldosterone and 1% NaCl after uninephrectomy. Glomeruli were enlarged with mesangial expansion in kidneys from (b) aldosterone-infused wild-type mice versus (a) those from wild-type mice infused with vehicle and (d) those from PAI-1(−/−) mice infused with aldosterone. (c) Comparison between the vehicle- and (d) aldosterone- infused PAI-1(−/−) kidneys suggests that PAI-1 deficiency protected against aldosterone-induced damage in this model. Aldosterone infusion also caused remarkable dilatation, hypertrophy, and hyperplasia of renal collecting tubules in both WT and PAI-1(−/−) kidneys with occasional calcium deposits (e). Bar=100 μm (periodic acid-Schiff). Kidney International 2006 69, 1064-1072DOI: (10.1038/sj.ki.5000201) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 Renal macrophage infiltration in wild-type and PAI-1(−/−) mice given aldosterone and 1% NaCl after uninephrectomy. There was scattered infiltration of macrophages in the renal interstitium in both vehicle-infused (a) wild-type and (c) PAI-1(−/−) mice. F4/80-positive macrophages were increased in the interstitium of kidneys from (b) wild-type and (d) PAI-1(−/−) mice infused with aldosterone. Bar=100 μm (antibody to F4/80). (e) Osteopontin mRNA signal (blue–purple) was detected in the collecting tubules (arrow) of aldosterone-treated WT mice. (f) In glomeruli of aldosterone-infused WT mice, osteopontin mRNA signal was detected on podocytes (black arrows) stained with WT-1 (brown) and capillary loop, consistent with endothelial cells (yellow arrow). Immunohistochemistry for PSmad2 (brown) showed increased staining in the (g) glomeruli of aldosterone-infused WT mice and (h) the tubules of aldosterone-infused PAI-1(−/−) mice. Kidney International 2006 69, 1064-1072DOI: (10.1038/sj.ki.5000201) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 4 Effect of aldosterone treatment on renal gene expression in wild-type (WT) and plasminogen activator inhibitor-1 (PAI-1)(−/−) mice. N was 5 or more per group. *P≤0.05 versus vehicle-infused WT, †P≤0.001 versus vehicle-infused PAI-1(−/−), ‡P≤0.008 versus vehicle-infused WT, §P<0.005 versus aldosterone-infused WT, ∥P<0.001 versus vehicle-infused WT, ¶P<0.05 versus aldosterone-infused WT, #P<0.05 versus vehicle-infused PAI-1(−/−). Kidney International 2006 69, 1064-1072DOI: (10.1038/sj.ki.5000201) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 5 Effect of aldosterone treatment on cardiac gene expression in wild-type (WT) and plasminogen activator inhibitor-1 (PAI-1)(−/−) mice. N was 5 or more per group. *P<0.001 versus vehicle-infused WT mice, †P<0.001 versus aldosterone-infused WT mice, ‡P<0.01 versus vehicle-infused WT mice, §P<0.05 versus aldosterone-infused WT mice, ∥P<0.01 versus vehicle-infused PAI-1(−/−) mice, ¶P<0.01 versus aldosterone-infused WT mice, #P<0.05 versus vehicle-infused PAI-1(−/−) mice, **P<0.05 versus either vehicle-infused groups, ††P<0.05 versus vehicle-infused WT. Kidney International 2006 69, 1064-1072DOI: (10.1038/sj.ki.5000201) Copyright © 2006 International Society of Nephrology Terms and Conditions